The Dynamics Mechanism of Vulnerability for Resource-based Enterprise Communities in China

This paper has analyzed the dynamics mechanism of resource enterprisescommunity vulnerability, selected the key factor of resources to establisha nonlinear dynamical model. The model reveals the constrained relationship between the number of vulnerable enterprises and resource shortagerate, and the same relationship between t vulnerable enterprise numbersand the owning rate of resource market by the biggest enterprise in resource-type enterprises community of China. The results showed that, theshortage rate of resources take up more percentage than the occupancy ofresource rate of the strongest enterprises in Enterprise community whenD>q. the characteristics and patterns of the Chinese enterprise evolutionare as follows, (1) The strongest enterprises n1 will decline or transformin the enterprise community. (2) The enterprises which survived after theshortage of resources will go through three stages: ① resistance stage;② recovery stage; ③ stable stage. We believe that there are three movements that can make sure the resource-based enterprises community keepgrowing continuously in the competitive market for resources, (1) understand the enterprise resources shortage rate and the strongest enterprisesshare in resource rate in enterprise community, (2) follow the even-oddsymmetry or odd-even symmetry laws based on the familiarity of a resource economy, (3) put the enterprises in the suitable position

The interplay of circulating tumor DNA and chromatin modification, therapeutic resistance, and metastasis

Abstract Peripheral circulating free DNA (cfDNA) is DNA that is detected in plasma or serum fluid with a cell-free status. For cancer patients, cfDNA not only originates from apoptotic cells but also from necrotic tumor cells and disseminated tumor cells that have escaped into the blood during epithelial-mesenchymal transition. Additionally, cfDNA derived from tumors, also known as circulating tumor DNA (ctDNA), carries tumor-associated genetic and epigenetic changes in cancer patients, which makes ctDNA a potential biomarker for the early diagnosis of tumors, monitory and therapeutic evaluations, and prognostic assessments, among others, for various kinds of cancer. Moreover, analyses of cfDNA chromatin modifications can reflect the heterogeneity of tumors and have potential for predicting tumor drug resistance